• Home
  • MyECTS
  • Become a member
  • Contact us

Ectsoc

Ecstoc.org

MENUMENU
  • About
    • Mission & Vision
    • Governance & Transparency
    • Board of Directors
    • Annual General Meeting
    • Committees and Action Groups
      • Executive Committee
      • Communications Committee
      • Community Engagement Committee
      • ECTS Academy
      • Education Committee
      • Clinical Science Committee
      • Research Committee
      • Scientific Programme Committee 2022
    • ECTS Team
    • Membership
      • Individual Membership
      • Corporate Supporters
      • Join us
      • Affiliated Societies
  • ECTS 2023
  • Events
    • Upcoming Congresses
    • Past Congress
    • ECTS Academy Charity Event
    • ICCBH
    • Events
  • Grants & Awards
  • Education
    • Education Resource Center
    • Clinical Training Course in Metabolic Bone Diseases
    • ECTS-Mellanby Training Course
    • Bone Muscle & Beyond Webinars
    • East-meets-West Online Symposium
    • Rare Bone Diseases Webinars
    • PhD Training Course
    • Calendar ECTS Educational Events
  • ECTS Academy
    • About the ECTS Academy
    • ECTS Academy Members
    • Call for Applications - Basic Scientists
    • Call for Applications - Clinicians
    • ECTS Academy Activities
      • NI Conference Program
      • ECTS Academy Webinar Series
      • ECTS Academy Mentoring Options
      • ECTS Academy Charity Run
    • Visit the ECTS Academy website
  • News
    • ECTS Newsletter
    • News
    • Press Release
    • Image Library
    • Video Library
    • Job Advertisements
You are here: Home / Education / E-learning / ECTS Webinar Series Bone, Muscle & Beyond / Pathophysiology and treatment of Autosomal Recessive Osteopetrosis: past, present and future

Pathophysiology and treatment of Autosomal Recessive Osteopetrosis: past, present and future

Pathophysiology and treatment of Autosomal Recessive Osteopetrosis: past, present and future

Live Webinar: 4 March 2021, 4 pm CET 

Jointly organised by ECTS & ECTS Academy

Date & Time:  4 March 2021, 4 pm CET

Featuring Anna Villa, and moderated by Bram van der Eerden

Costs: Live webinar is free for ECTS members and non-members, but a registration is required. Recordings are accessible to ECTS members only.

Format:

  • 5 min welcome & introductions
  • 35 min presentation on Osteopetrosis
  • 20 min Q&A

Learning Objectives:

  • To learn molecular basis of Osteoclast rich and Osteoclast poor Osteopetrosis
  • To understand the gold standard therapy
  • To learn preclinical model of innovative therapeutic strategies

Register

 

The Osteopetrosis, Brussels, Belgium, 04-03-2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s).
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Additional Live Coffee Shop: 4 March 2021, 5 pm CET

ECTS is pleased to invite you for an additional “Coffee Shop” informal discussion at 5 pm CET, right after the live webinar, in order to meet friends and colleagues with an interest in the bone field for a topical chat.

Please register for the live webinar and the additional Zoom link for this Coffee Shop will be sent in the confirmation email as well as in a reminder sent 2 hours in advance of the webinar.

Featuring Anna Villa

Anna Villa received her medical degree in 1986 at University of Milan and completed her medical and research fellowship at National Research Council in Milano where she is currently Research Director. Her team has identified TCIRG1 as the gene responsible for Autosomal Recessive Osteopetrosis (ARO) and later on she contributed to the characterization of two other forms of ARO due to defect in Grey Lethal and Pleckstrin genes. She identified RANKL and RANK as genes responsible for the osteoclast-poor Osteopetrosis. More recently, her group has tested and optimized a novel strategy to correct TCIRG1 gene defect by generating a third-generation lentiviral vector carrying human TCIRG1 gene to cure the most frequent form of ARO.  Experiments to scale up gene therapy approach and move to the clinical application are currently ongoing. Currently, Dr. Villa is Head of Unit of the “Pathogenesis and Treatment of Immune and Bone diseases” at Telethon Institute for Gene Therapy, San Raffaele Hospital Milano, Italy.

Moderated by Bram van der Eerden

Bram van der Eerden studied Biology in Utrecht (the Netherlands) and received his PhD in 2002 in Leiden (the Netherlands) working on the hormonal regulation of growth plate cartilage. Since then, he has been working within the department of Internal medicine of the Erasmus MC in Rotterdam on the role of calcium channels in bone and is now mainly involved in the functional characterization of novel compounds/genes/pathways that are anabolic to bone, using in vitro and in vivo models. Currently, he is group leader of the laboratory for Calcium and Bone Metabolism of Internal Medicine at the Erasmus MC. Bram has (co)-authored >50 peer-reviewed papers, has been board member of the Dutch Calcium and Bone Metabolism Society (NVCB) for 6 years and is now in the Bone networking group of the Dutch Society for Endocrinology. He was co-chair of the IBMS young investigator committee and is currently chairing the ECTS Webinar Committee. He has been involved in a number of international projects, including an ongoing Horizon2020 Marie-Curie Staff Exchange project (RUBICON) focusing on the molecular pathways in connective tissue diseases. His research group consists of 2 senior scientists, 1 Post-doc, 4 PhD students and 2 technicians.

Abstract

Autosomal recessive osteopetrosis (ARO) is a severe inherited bone disease characterized by defective osteoclast resorption or differentiation. Clinical manifestations include dense and brittle bones, anaemia and progressive nerve compression, hampering their quality of life and causing death in the first ten years of age. Molecular bases are heterogenous posing clinical issues on the treatment of some ARO forms. Here I will summarize the pathogenesis of ARO and highlight strengths and weakness of the current standard of care, namely hematopoietic stem cell transplantation (HSCT). Despite the overall survival and outcomes of HSCT are improving, transplant related morbidity and pre-existence of neurological symptoms significantly limit the success of HSCT, while availability of HLA-matched donors still remains an open issue. Novel therapeutic approaches are needed for ARO patients, especially for those who cannot benefit from HSCT. I will revise preclinical studies paving the road map to the development of innovative clinical therapies and broad the current therapeutic scenario.

Copyright 2016 ECTS - Disclaimer - Cookies Policy - Privacy Policy - Privacy Centre - Terms of use - Contact us
This website uses cookies to improve user experience. Read about how we use cookies and how you can control them by clicking “Change Cookie Settings” or accept cookies by clicking “Accept Cookies”. Read more
Accept Cookies
Change Cookie Settings
Cookie Box Settings
Cookie Box Settings
Decide which cookies you want to allow. You can change cookie setting at any time. However, this can result in some functions no longer being available. Learn more about the cookies we use.

You can opt in by clicking on the cookie types below:

  • Block all
  • Essential
  • Functionality
  • Analytics
  • Advertising

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Authenticate that you are logged into your user account

This website won

  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Functionality: Remember language version you selected
  • Functionality: Identify device you are using
  • Analytics: Keep track of your visited pages
  • Analytics: Keep track about your location and region based on your IP address
  • Analytics: Keep track on the time spent on each page
  • Analytics: Identify device you are using
  • Advertising: Allow you to connect to social sites
  • Advertising: Gather personally identifiable information
  • Remember your login details

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Authenticate that you are logged into your user account
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Functionality: Remember language version you selected
  • Functionality: Identify device you are using

This website won

  • Analytics: Keep track of your visited pages
  • Analytics: Keep track about your location and region based on your IP address
  • Analytics: Keep track on the time spent on each page
  • Analytics: Identify device you are using
  • Advertising: Allow you to connect to social sites
  • Remember your login details
  • Advertising: Gather personally identifiable information

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Authenticate that you are logged into your user account
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Functionality: Remember language version you selected
  • Functionality: Identify device you are using
  • Analytics: Keep track of your visited pages
  • Analytics: Keep track about your location and region based on your IP address
  • Analytics: Keep track on the time spent on each page
  • Analytics: Identify device you are using

This website won

  • Advertising: Allow you to connect to social sites
  • Advertising: Gather personally identifiable information
  • Remember your login details

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Authenticate that you are logged into your user account
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Functionality: Remember language version you selected
  • Functionality: Identify device you are using
  • Analytics: Keep track of your visited pages
  • Analytics: Keep track about your location and region based on your IP address
  • Analytics: Keep track on the time spent on each page
  • Analytics: Identify device you are using
  • Advertising: Allow you to connect to social sites
  • Advertising: Gather personally identifiable information

This website won

  • Remember your login details
Save & Close